Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.45 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Pyrrolidone SCHEMBL4595907 | 1.00 | OR51E2 (0.52) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL933908 | 0.98 | OR51E2 (0.50) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL28565455 | 0.98 | OR51E2 (0.50) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL27876042 | 0.95 | OR51E2 (0.47) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL852356 | 0.91 | OR51E2 (0.43) | OR51E2CRBNFKBP5ALDH1A1 | |
| Caprolactam SCHEMBL28156132 | 0.88 | FKBP5 (0.46) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL27365042 | 0.85 | OR51E2 (0.47) | OR51E2CRBNFKBP5KDM4EGAA | |
| Itaconate SCHEMBL4960729 | 0.85 | ALOX15 (0.40) | OR51E2CRBNFKBP5 | |
| 2-Pyrrolidone SCHEMBL28279632 | 0.83 | OR51E2 (0.48) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL3378461 | 0.83 | OR51E2 (0.52) | OR51E2CRBNFKBP5KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 547 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199933-A1 | A FIBRE BINDER COMPOSITION FOR RETAINING FIBRES AND OTHER PARTICLES ON A BUILDING SITE | ADMANSTARS B.V (NL) | 2024-06-20 | — | — | US | claimed |
| EP-4323453-A1 | A FIBRE BINDER COMPOSITION FOR RETAINING FIBRES AND OTHER PARTICLES ON A BUILDING SITE | Fiberbinder ApS (DK) | 2024-02-21 | — | — | EP | claimed |
| US-20230398108-A1 | Pharmaceutical Compositions of a Kinase Inhibitor | EXELIXIS, INC. | 2023-12-14 | — | — | US | claimed |
| EP-4240333-A1 | PHARMACEUTICAL COMPOSITIONS OF A KINASE INHIBITOR | Exelixis, Inc. (US) | 2023-09-13 | — | — | EP | claimed |
| CN-116710092-A | Composition for oral administration of efroconazole | 大峰LS株式会社 | 2023-09-05 | — | — | CN | claimed |
| US-11666514-B2 | Fibrous structures containing polymer matrix particles with perfume ingredients | THE PROCTER & GAMBLE COMPANY (US) | 2023-06-06 | — | — | US | claimed |
| CN-115710559-A | Methods and compositions for improving corn yield | 新叶共生有限公司 | 2023-02-24 | — | — | CN | claimed |
| EP-4017563-A1 | NITRIC OXIDE GENERATING SYSTEMS | Nota Laboratories, LLC (US) | 2022-06-29 | — | — | EP | claimed |
| US-20220176062-A1 | NITRIC OXIDE GENERATING SYSTEMS | NOTA Laboratories, LLC | 2022-06-09 | — | — | US | claimed |
| CN-110636837-B | Pharmaceutical composition of CYP17 inhibitor and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2022-05-24 | — | — | CN | claimed |
| WO-2005123024-A1 | TOOTH WHITENING PRODUCTS AND METHODS OF MAKING THE SAME | LORNAMEAD BRANDS, INC. (US) | 2005-12-29 | — | — | WO | claimed |
| US-20050276760-A1 | Tooth for whitening products and methods of making the same | LORNAMEAD BRANDS, INC. (US) | 2005-12-15 | — | — | US | claimed |
| US-20020100725-A1 | Method for preparing thin fiber-structured polymer web | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2002-08-01 | — | — | US | claimed |
| WO-2001006011-A2 | ARRAYS COMPRISING NON-COVALENTLY ASSOCIATED NUCLEIC ACID PROBES AND METHODS FOR MAKING AND USING THEM | GENOMETRIX GENOMICS, INC. (US) | 2001-01-25 | — | — | WO | claimed |
| EP-0557087-B1 | Aqueous aerosol hair-spray compositions with a relatively low content of volatile organic compounds | REVLON CONSUMER PROD CORP (US) | 1995-12-06 | — | — | EP | claimed |
| US-5095054-A | Molding premixes of a melt of a degraded starch and hydrophobic water-insoluble thermoplastic polymer; dimensional stability; toughness; humidity resistance; receptivity | WARNER-LAMBERT COMPANY (US) | 1992-03-10 | — | — | US | claimed |
| EP-0407350-A2 | Polymer base blend compositions containing destructurized starch | WARNER-LAMBERT COMPANY (US) | 1991-01-09 | — | — | EP | claimed |
| EP-0064388-B1 | RETARD ORAL PHARMACEUTICAL COMPOSITIONS | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1985-11-06 | — | — | EP | claimed |
| EP-0064388-A2 | Retard oral pharmaceutical compositions | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1982-11-10 | — | — | EP | claimed |
| US-4108185-A | HYDROSOLUBLE POLYMER | L'OREAL (FR) | 1978-08-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398108-A1 | Pharmaceutical Compositions of a Kinase Inhibitor | MET, MINK1, PEAK1 | OR51E2 3871/4885CRBN 604/4885FKBP5 2404/4885 |
| US-11666514-B2 | Fibrous structures containing polymer matrix particles with perfume ingredients | FSCN1, FLNA, PFN1 | OR51E2 2939/4885CRBN 3544/4885FKBP5 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.